key: cord-0711850-04dwuxud authors: Turelli, P.; Zaballa, M. E.; Raclot, C.; Fenwick, C.; Kaiser, L.; Eckerle, I.; Pantaleo, G.; Guessous, I.; Stringhini, S.; Trono, D. title: Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing activity date: 2022-05-02 journal: nan DOI: 10.1101/2022.05.02.22274436 sha: dfd03ba04b608204bdcfdd103eb7e4ab3cdbd9fd doc_id: 711850 cord_uid: 04dwuxud Background: The rapid worldwide spread of the mildly pathogenic SARS-CoV-2 Omicron variant has led to the suggestion that it will induce levels of collective immunity that will help putting an end to the COVID19 pandemics. Methods: Convalescent serums from non-hospitalized individuals previously infected with Alpha, Delta or Omicron BA.1 SARS-CoV-2 or subjected to a full mRNA vaccine regimen were evaluated for their ability to neutralize a broad panel of SARS-CoV-2 variants. Findings: Prior vaccination or infection with the Alpha or to a lesser extent Delta strains conferred robust neutralizing titers against most variants, albeit more weakly against Beta and even more Omicron. In contrast, Omicron convalescent serums only displayed low level of neutralization activity against the cognate virus and were unable to neutralize other SARS-CoV-2 variants. Interpretation: Moderately symptomatic Omicron infection is only poorly immunogenic and does not represent a substitute for vaccination. Omicron (also referred to as BA.1 or B.1.1.529) was identified as a new SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) variant in late 2021 and rapidly became dominant so as to account today for a large majority of new infections worldwide 1 . Omicron differs from previously prevalent SARS-CoV-2 variants at more than thirty amino acid positions within Spike, the protein responsible for mediating viral entry through recognition of the ACE2 receptor and targeted by SARS-CoV-2 neutralizing antibodies. Accordingly, Omicron escapes neutralization by most monoclonal antibodies available for the treatment of COVID19 or by pre-Omicron convalescent sera and can readily cause infections in individuals who have been either previously infected with other SARS-CoV-2 variants or subjected to full vaccination regimens, all current vaccines being derived from the original SARS-CoV-2 strain or from close relatives [2] [3] [4] [5] [6] [7] . Likely due to a combination of these immunological features and of variant-specific virological properties, Omicron is highly contagious yet generally causes milder symptoms compared with other SARS-CoV-2 variants including its immediate predecessor Delta 8,9 . This has led to the hope that the sweeping propagation of Omicron in the world population might contribute to put an end to the COVID19 pandemics by inducing, at a low cost for global health, robust levels of protective immunity including in non-vaccinated populations. As a step towards probing this hypothesis, we measured levels of variant-specific neutralizing antibodies in the serum of a group of 23 individuals recently infected with Omicron without reported prior exposure to or vaccination against SARS-CoV-2, and whose infection did not require hospitalization (table 1) Omicron convalescent sera, 17 and 20 were positive for anti-S and anti-N antibodies, respectively, albeit to a low level, strongly suggesting a lower global humoral immune response after infection by this compared with other variants. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) and A222V mutations, but were much less effective against Beta and even more so against the three Omicron subvariants (figure 1G). After Omicron infection, SARS-CoV-2 neutralizing titers were uniformly lower and displayed no significant activity against any of the ten other Spike variants tested through this assay. Further and concerningly, only 4 and 9 out of 23 individuals displayed titers around the 1:50 ED50 cut-off against BA.1 and its BA.1.1 sublineage, respectively, with for all an additional major reduction in BA.2 Spike neutralization ( figure 1H ). Finally, sera from mRNA-vaccinated individuals were strongly neutralizing against most variants but were significantly less potent against Beta and even more markedly against the 3 Omicron sublineages ( Figure 1h ). Noteworthy, in none of these subgroups of individuals were anti-S serological titers predictive of variant-neutralizing activity (appendix p 1). To consolidate further these data, we used a cell-based neutralisation assay with Omicron BA.1 live virus ( figure 2A) . None of the Alpha-convalescent sera was able to neutralize this variant, even at the starting 1:10 dilution. Some prevention of virus-induced cytopathic effect (CPE) was obstained with the 2 Delta-convalescent sera (D-1 and D-2) found to have the highest neutralization titers against Omicron Spike in the cell-free assay (ED50%=64 and 52 respectively). Finally, low levels of Omicron-neutralizing activity (serum dilution 1:10 to 1:30 max.) were detected in 17 of the 23 Omicron-convalescent individuals, the same previously identified as displaying an ED50%>=7.8 in our cell-free assay. We extended this analysis by selecting the 5 serums from previously Omicron-infected individuals with the highest anti-S . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In sum, these data indicate that Omicron infection generally induces on its own only low levels of neutralizing antibodies in immunocompetent individuals, and that these antibodies further display a narrow range of activity. The former may partly be related to the usual mildness of Omicron-induced symptoms and possibly to its replication in less immunogenic sites, and the latter to antigenic features differing markedly between the Spike proteins of Omicron and that of other SARS-CoV-2 variants 8,11 . Critically, our results indicate that the widespread propagation of Omicron is unlikely to induce the levels of protective collective immunity needed to curb the COVID19 pandemics, and should serve as a warning against using Omicron exposure as a surrogate for vaccination. Serum neutralizing antibody titers are considered as the most significant biomarker of protective immunity against SARS-CoV-2 infection 12 . To our knowledge, only one recent peerreviewed study has examined levels of neutralizing activity induced by Omicron infection only, but this study was limited to 20 hospitalized patients, that is, belonging to the small minority of Omicron-infected individuals presenting with serious disease hence more likely to mount a robust immune response 13 . In contrast, our analysis was restricted to individuals whose symptoms did not require hospitalization, that is, much more representative of a typical course of Omicron infection. No serum was available from individuals previously infected with the Omicron BA.2 subvariant, which only recently emerged in our region. Although we did not have the sequence of the infecting virus, all serums were harvested at times during which the Alpha, Delta and Omicron BA.1 variants, respectively, overwhelmingly predominated in the local population (>95%, see Methods). Convalescent serums were harvested on average 20, 54 and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.05.02.22274436 doi: medRxiv preprint 39 days post Alpha, Delta and Omicron infections respectively, so that we cannot exclude that neutralizing titers had not yet reached their peak in all cases. However, previous studies indicate that antibody responses are already robust three weeks after SARS-CoV-2 infection 14,15 , which suggests that the the low titers in neutralizing antibodies of serums from our Omicron-convalescent group can not be inferred to collection time . Finally, our sample did not include individuals whose symptoms had required hospitalization, which may explain why their Omicron-directed neutralization response was weaker than recently reported for a small group of hospitalized patients 13 . Serum samples were obtained from participants of the Specchio-COVID19 cohort. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.05.02.22274436 doi: medRxiv preprint foldon fusion domain to stabilize the trimer complex followed by C-terminal 8x His and 2x Strep tags for affinity purification. The trimeric Spike variants were produced and purified as previously described 10 . Trimeric-Spike variants production and purification and Spike protein beads coupling were performed as previously described 10 . Neutralization assays were done in 96-well plates as previously described 10 , with 10 multiplexed Spike variants and 8 µl of serum per well for the starting dilution. Briefly, 1:3 serial dilutions of sera were incubated 1 hour with the Spikes before ACE2 mouse Fc fusion protein (produced and purified as previously described 10 ) was is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.05.02.22274436 doi: medRxiv preprint Neutralization assay was performed as previously described 18 except that serial sera dilutions were done in EPISERF instead of DMEM 2% FCS. In brief, 3000 plaque forming units per well of viral isolate were pre-incubated for 1 hour @ 37°C with 1:3 serial dilutions of sera prepared in duplicates in 96-well plates. The mix was then applied on VeroE6 cells and cytopathic effect detected 48hours later with Crystal violet staining. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. C . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.05.02.22274436 doi: medRxiv preprint Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies We thank Florence Pojer and the Protein production and structure Core facility at EPFL for Alpha 41-50 f na 17 17 5 mild >5 1 to 2 weeks A-2 Alpha 41-50 f na 32 61 50 mild 1 to 5 1 to 2 weeks A-3 Alpha 41-50 f na 13 55 14 mild 1 to 5 1 to 2 weeks A-4 Alpha 41-50 f na 25 5 22 mild na na A-5 Alpha 31-40 f na 17 13 171 moderate >5 <3 weeks A-6 Alpha 31-40 m na 23 13 39 moderate na na A-7 Alpha 31-40 f na 17 47 72 severe >5 1 to 2 weeks A-8 Alpha 31-40 f na 41 27 46 moderate >5 1 to 2 weeks A-9 Alpha 41-50 f na 41 105 180 mild na 1 to 2 weeks A-10 Alpha 31-40 m na 10 61 11 moderate na <2 weeks D-1 Delta 71-80 f na 20 40 648